Get the Stockscreener App
0.753
0.40%
0.003
Xilio Therapeutics Inc stock is traded at $0.753, with a volume of 229.93K.
It is up +0.40% in the last 24 hours and down -0.32% over the past month.
Xilio Therapeutics Inc is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. The company is using its proprietary platform to advance a pipeline of novel, tumor-activated clinical and preclinical I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines and antibodies and immune cell engagers.
See More
Previous Close:
$0.75
Open:
$0.75
24h Volume:
229.93K
Relative Volume:
0.31
Market Cap:
$39.53M
Revenue:
-
Net Income/Loss:
$-81.22M
P/E Ratio:
-0.2544
EPS:
-2.96
Net Cash Flow:
$-74.41M
1W Performance:
+6.48%
1M Performance:
-0.32%
6M Performance:
-9.82%
1Y Performance:
-18.15%
1-Day Range:
$0.7392
$0.7594
1-Week Range:
$0.6811
$0.807
52-Week Range:
$0.615
$1.70
Xilio Therapeutics Inc Stock (XLO) Company Profile
Name
Xilio Therapeutics Inc
Sector
Industry
Phone
617-833-1027
Address
828 WINTER STREET, WALTHAM
Compare XLO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XLO
Xilio Therapeutics Inc
|
0.753 | 39.38M | 0 | -81.22M | -74.41M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
426.76 | 107.15B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.90 | 77.46B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
436.38 | 58.90B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
918.92 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
198.76 | 42.58B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xilio Therapeutics Inc Stock (XLO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-06-25 | Initiated | Leerink Partners | Outperform |
| Dec-21-22 | Initiated | Chardan Capital Markets | Buy |
| Jan-10-22 | Initiated | H.C. Wainwright | Buy |
| Nov-16-21 | Initiated | Cowen | Outperform |
| Nov-16-21 | Initiated | Guggenheim | Buy |
| Nov-16-21 | Initiated | Morgan Stanley | Overweight |
| Nov-16-21 | Initiated | Raymond James | Outperform |
View All
Xilio Therapeutics Inc Stock (XLO) Latest News
Is Xilio Therapeutics Inc. stock a buy before product launchesJuly 2025 Rallies & Low Drawdown Momentum Ideas - newser.com
How institutional buying supports Xilio Therapeutics Inc. stockMarket Performance Report & High Accuracy Trade Alerts - newser.com
Is Xilio Therapeutics Inc. stock resilient to inflationWeekly Trade Report & Low Risk High Reward Trade Ideas - newser.com
Is Xilio Therapeutics Inc a good long term investmentFundamental Stock Analysis & Free Technical Analysis and Insights - earlytimes.in
Can Samtex Fashions Limited Outperform Index Funds Over the Next 5 YearsEmerging Market Stocks & Free Rapid Profit Acceleration - earlytimes.in
Is ACRS a good long-term investment? - earlytimes.in
Tick level data insight on Xilio Therapeutics Inc. volatilityGlobal Markets & Stock Timing and Entry Methods - newser.com
How Xilio Therapeutics Inc. stock compares to market leadersWeekly Gains Report & High Accuracy Trade Signal Alerts - newser.com
Why Xilio Therapeutics Inc. stock remains on watchlists2025 Buyback Activity & Fast Gain Swing Alerts - newser.com
Xilio Therapeutics Reports Revenue Growth Amidst Challenges - MSN
Why Xilio Therapeutics Inc. stock is in analyst buy zoneTrade Exit Summary & Verified Entry Point Signals - newser.com
How geopolitical tensions affect Xilio Therapeutics Inc. stock2025 Macro Impact & Daily Stock Momentum Reports - newser.com
Is Xilio Therapeutics Inc. stock safe for conservative investorsJuly 2025 Highlights & Daily Stock Trend Watchlist - newser.com
Is it too late to sell Xilio Therapeutics Inc.2025 Market Trends & AI Forecasted Entry and Exit Points - newser.com
Is it time to cut losses on Xilio Therapeutics Inc.Portfolio Value Report & Daily Technical Stock Forecast Reports - newser.com
Published on: 2025-11-19 00:08:23 - newser.com
Building trade automation scripts for Xilio Therapeutics Inc.July 2025 Review & Risk Controlled Stock Alerts - newser.com
Tools to assess Xilio Therapeutics Inc.’s risk profileInsider Selling & Real-Time Stock Movement Alerts - newser.com
What drives WHLRD stock priceDouble Top/Bottom Patterns & Low Risk Trading Plans - earlytimes.in
Top Growth Drivers Behind Omnitex Industries India Limited Stocks Recent SurgeRisk Mitigation Techniques & Affordable Market Insights - earlytimes.in
What makes Xilio Therapeutics Inc. stock attractive to growth fundsFed Meeting & Risk Managed Investment Entry Signals - newser.com
What machine learning models say about Xilio Therapeutics Inc.July 2025 Macro Moves & Daily Growth Stock Tips - newser.com
Published on: 2025-11-15 13:28:14 - newser.com
Best data tools to analyze Xilio Therapeutics Inc. stockBreakout Watch & Weekly Chart Analysis and Guides - newser.com
Published on: 2025-11-15 00:01:21 - newser.com
Xilio Therapeutics, Inc. (XLO) Reports Q3 Loss, Misses Revenue Estimates - sharewise.com
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Applied Therapeutics (APLT) and Xilio Therapeutics (XLO) - The Globe and Mail
What Fibonacci levels say about Xilio Therapeutics Inc. reboundJuly 2025 Movers & AI Optimized Trade Strategies - newser.com
Xilio Therapeutics Banks More Revenue But Spends Heavily On Research - Finimize
Xilio Therapeutics Inc Stock (XLO) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.38%
1.42%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):